Name: how bacteria outsmart antibiotics
Uploaded: 2026-03-12T13:35:59.000Z
Duration: 1 min 25 s
Channel: JoVE

황색포도상구균은 인간 피부에서 흔히 발견되지만, 기회주의 병원체입니다.메티실린 내성 황색포도상구균( MRSA)은 메티실린 및 페니실린과 같은 대부분의 β락탐 항생제에 내성을 가진 S. aureus 의 한 종류입니다.MRSA 균주는 대부분의 β-락탐이 표적으로 하는 페니실린 결합 단백질(PBP)을 변형시킵니다.MRSA 균주에서는 이 내성이 발달하는데, mecA 유전자는 변형된 페니실린 결합 단백질인 PBP2a를 암호화합니다.이 변형된 PBP2a는 베타-락탐 항생제에 대한 결합 친화력이 낮아, MRSA가 이 약물이 존재하더라도 세포벽을 합성할 수 있게 합니다.많은 MRSA 균주에서 mecA 발현을 조절하는 조절 유전자인 mecI와 mecR1은 기능을 하지 않습니다.이로 인해 PBP2a의 연속적 발현과 안정적인 내성이 발달합니다.MRSA는 박테리아 집단 중 일부만 내성을 나타내는 이질적 내성이거나, 전체 집단이 내성을 보이는 균질성 내성을 보일 수 있습니다.

mrsa에서 항생제 내성의 기전

Mechanism of Antibiotic Resistance in MRSA

박테리아의 항생제 내성은 미생물이 자신을 죽이거나 성장을 억제하는 약물을 견딜 수 있는 능력을 진화시켜 한때 효과적이었던 치료가 무용지물이 되면서 발생합니다. 이 현상은 유전적 변화와 항생제 노출 하에서의 선택에 의해 촉발되며, 현대 의학에 심각한 위협을 가합니다. 기전에는 약물 비활성화 효소(예: β-락타마제), 항생제를 배출하는 배출 펌프, 항생제 표적을 변화시키는 돌연변이, 약물 흡수 감소, 수평 유전자 전달을 통한 내성 유전자 획득 등이 포함됩니다. 내성은 돌연변이를 통해 새로 발생하거나 플라스미드나 트랜스포존과 같은 이동성 유전 요소를 통해 빠르게 전파될 수 있습니다. 항생제의 남용과 과다 사용으로 인한 선택 압력은 내성 균주의 출현과 확산을 가속화합니다.임상적으로 항생제 내성 감염은 치료가 더 어렵고, 더 독성이 강하거나 비싼 약물이 필요하며, 입원 기간을 연장하고, 의료비를 높이며, 이환율과 사망률을 증가시킵니다. 전 세계 추정치는 저항 추세가 계속될 경우 매년 수백만 명이 사망할 것이라고 경고하고 있습니다.메티실린 내성 황색포도상구균(MRSA) MRSA는 항생제 내성의 전형입니다. SCCmec 요소를 통해 mecA 유전자를 획득함으로써, S. aureus는 변성된 페니실린 결합 단백질인 PBP2a를 생성하는데, 이 단백질은 β-락탐 약물에 결합하지 않아 페니실린, 세팔로스포린, 카바페넴에 대한 광범위한 내성을 부여합니다. MRSA는 병원(HA-MRSA)에서, 이후 지역사회(CA-MRSA)에서 돌연변이와 수평 유전자 전달에 의해 발생했습니다. 임상적으로 MRSA는 심각한 피부, 연조직, 혈류 및 폐렴 감염을 일으키며, 종종 반코마이신, 댑토마이신, 또는 리네졸리드로 치료하지만, 이들 대체 치료법에는 한계가 있습니다.박테리아에서 항생제 내성의 다른 예시들:반코마이신 내성 장구균(VRE)과 VRSA 반코마이신에 내성을 가진 장구균은 반 유전자 오페론(예: vanA)의 획득을 통해 나타났습니다. 이 유전자들은 S. aureus로 추가로 이전되어 드물지만 위험한 반코마이신 내성 S. aureus (VRSA) 균주가 탄생했습니다. VRSA 감염은 대안이 제한적이기 때문에 치료가 어렵고, 드물음에도 불구하고 심각한 임상적 우려를 받고 있습니다.약제 내성 연쇄상구균 폐 렴(DRSP) S. pneumoniae 는 페니실린 결합 단백질의 돌연변이를 통해 페니실린에 내성을 발달시켰고, 메틸트랜스퍼라제 유전자를 통해 마크로라이드에 내성을 발달시켰습니다. 이러한 변화는 폐렴, 수막염, 중이염 치료 효과를 감소시켜, 세팔로스포린이나 플루오로퀴놀론과 같은 고등급 항생제가 필요해졌으며, 이들 약물 역시 고유한 위험을 동반합니다.요약하자면, 항생제 내성은 유전적 적응과 유전자 교환을 통해 진화하며, MRSA, VRE/VRSA, DRSP 등 주요 병원체에 걸쳐 중요한 임상적 영향을 미칩니다. 적절한 항생제 사용, 내성 패턴 감시, 감염 통제, 신규 치료제 개발은 이 증가하는 공중보건 위기를 완화하기 위해 여전히 필수적입니다.

MRSA에서 항생제 내성의 기전

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, ...

https://cloudfront.jove.com/files/ftp_upload/40835/40835_article_thumb_40835.jpg

mechanism-of-antibiotic-resistance-in-mrsa

Education

교육

JoVE Core

Microbiology

미생물학

Unit

단위

Antimicrobial Agents

항균제

KEY TERMS AND CONCEPTS

주요 용어 및 개념

how bacteria outsmart antibiotics

Antibiotic resistance in bacteria happens when microbes evolve the ability to survive drugs that once killed them or slowed their growth. Genetic change and antibiotic exposure drive this process. Over time, useful treatments can stop working.

Bacteria can resist antibiotics in several ways. Some make drug-inactivating enzymes, such as beta-lactamases. Others use efflux pumps to push antibiotics out of the cell. Resistance can also come from mutations that change the drug target, from lower drug uptake, or from new resistance genes gained through horizontal gene transfer, which is the movement of DNA between organisms.

Resistance may appear through new mutations or spread quickly through mobile genetic elements like plasmids and transposons. Misuse and overuse of antibiotics increase selection pressure, which helps resistant strains survive and spread. This makes antibiotic-resistant infections harder to treat and often forces doctors to use more toxic or more expensive drugs. These infections can also lead to longer hospital stays, higher healthcare costs, and more illness and death.

MRSA, short for methicillin-resistant Staphylococcus aureus, is a well-known example of this process. It acquired the mecA gene through the SCCmec element and makes an altered penicillin-binding protein called PBP2a. Because PBP2a does not bind beta-lactam drugs well, MRSA resists penicillins, cephalosporins, and carbapenems. MRSA first spread in hospitals as HA-MRSA and later in communities as CA-MRSA. It can cause skin, soft-tissue, bloodstream, and pneumonia infections, and it is often treated with vancomycin, daptomycin, or linezolid, although these options have limits.

Other resistant bacteria show the same problem in different forms. Vancomycin-resistant enterococci can gain van genes, such as vanA, and those genes can transfer to S. aureus to create rare but dangerous VRSA strains. Streptococcus pneumoniae can become resistant to penicillin through changes in penicillin-binding proteins and to macrolides through methyltransferase genes. These changes can make pneumonia, meningitis, and otitis media harder to treat and may require higher-tier antibiotics such as cephalosporins or fluoroquinolones.

Antibiotic resistance grows through genetic adaptation and gene exchange. Its impact reaches major pathogens such as MRSA, VRE, VRSA, and drug-resistant S. pneumoniae. Careful antibiotic use, resistance surveillance, infection control, and new treatments are important ways to slow this public health threat.

How Bacteria Outsmart Antibiotics

inhibitors of gram-positive cell wall synthesis

inhibitors-of-gram-positive-cell-wall-synthesis

How Antibiotics Block Bacterial Cell Walls

Bacterial cell walls are rigid structures built mainly from peptidoglycan. This mesh-like polymer gives bacteria strength and helps maintain cell shape. Because peptidoglycan synthesis is essential for growth, it is a major target for antibiotics. Beta-lactam antibiotics, such as penicillin, stop peptidoglycan synthesis in actively growing cells. They have a four-membered beta-lactam ring that mimics the D-alanyl-D-alanine dipeptide, which is the natural substrate for transpeptidase, also...

inhibitors of bacterial protein synthesis

inhibitors-of-bacterial-protein-synthesis

Aminoglycosides: How They Stop Bacteria

Aminoglycosides are bactericidal antibiotics that stop bacteria by targeting the ribosome and disrupting protein synthesis. They are highly potent drugs made of amino-modified sugars linked by glycosidic bonds to an aminocyclitol core, such as 2-deoxystreptamine or streptamine. Their strong positive charge helps them bind tightly to the negatively charged phosphate backbone of ribosomal RNA, especially the 16S rRNA of the 30S subunit in the bacterial 70S ribosome. These antibiotics act at the...

inhibitors of bacterial dna synthesis

Fluoroquinolone Antibiotics and Bacterial DNA

Fluoroquinolone antibiotics target bacterial DNA replication by blocking two key type II topoisomerases: DNA gyrase and topoisomerase IV. These enzymes help bacteria manage DNA supercoiling and separate chromosomes during replication. When they are disrupted, bacterial pathogens cannot copy DNA efficiently and infection can spread less effectively. Fluoroquinolones are synthetic versions of quinolones. They work by stabilizing the short-lived DNA-enzyme cleavage complex, which stops strand...

inhibitors of viral protein synthesis

Interferons Block Viral Replication

Interferons block viral replication by shutting down protein synthesis and activating the cell’s antiviral defenses. Viruses need the host cell’s translational machinery to make proteins, because they do not have the machinery to do this on their own. When a virus is detected, infected cells release interferons, which are cytokines, or signaling proteins, that warn nearby uninfected cells. Interferons bind to receptors on nearby cells and activate the JAK-STAT signaling pathway. This turns on...

inhibitors of virion release

Neuraminidase Inhibitors and Flu Spread

Influenza viruses spread when new virions leave an infected cell and reach nearby cells. Influenza A and B are negative-sense, single-stranded RNA viruses with segmented genomes. They depend on two surface glycoproteins, hemagglutinin (HA) and neuraminidase (NA), to infect cells, make new viral particles, and release them. HA starts infection by binding to sialic acid on the surface of host epithelial cells. This binding helps the virus enter the cell by receptor-mediated endocytosis. After...

antiviral nucleoside inhibitors

How Antiviral Drugs Stop Viral Replication

Antiviral nucleoside inhibitors stop viruses by blocking DNA or RNA synthesis. These drugs are structural analogs, which means they look like natural nucleosides, the building blocks cells use to make genetic material. Because they resemble host nucleosides, they can interfere with viral polymerases and disrupt viral genome replication. Acyclovir is a guanosine analog with a three-carbon acyclic side chain. It mainly targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2...

antifungal agents

Amphotericin B and Fungal Membranes

Amphotericin B targets fungal cell membranes by binding to ergosterol, a sterol found mainly in fungal plasma membranes. Its amphipathic structure helps this selective binding. It has a hydrophobic polyene-lactone ring and a hydrophilic region with mycosamine and carboxylic acid groups. Weak binding to cholesterol can also affect human cells and helps explain the drug’s toxicity. One way amphotericin B kills fungi is through pore formation. In this model, amphotericin B-ergosterol complexes...

mechanism of antibiotic resistance in mrsa

Antibiotic resistance in bacteria happens when microbes evolve the ability to survive drugs that once killed them or slowed their growth. Genetic change and antibiotic exposure drive this process. Over time, useful treatments can stop working. Bacteria can resist antibiotics in several ways. Some make drug-inactivating enzymes, such as beta-lactamases. Others use efflux pumps to push antibiotics out of the cell. Resistance can also come from mutations that change the drug target, from lower...

anthelminthic agents

Helminth Drugs and How They Work

Helminth drugs work by attacking the weak points of parasitic worms. These anthelmintic medicines are different from drugs used against protozoa, because they are usually aimed at mature helminths rather than fast-dividing cells. They target the worm’s movement, glucose use, and microtubule structure to stop survival, reproduction, and location inside the host. Benzimidazoles are broad-spectrum anthelmintics that block tubulin polymerization, which means they interfere with microtubules, the...

clinical significance of antibiotic resistance

clinical-significance-of-antibiotic-resistance

MRSA: Host Adaptation and Transmission

MRSA, or methicillin-resistant Staphylococcus aureus, is a major public health threat. It resists beta-lactam antibiotics because it carries the mecA gene inside the staphylococcal cassette chromosome mec, or SCCmec. The mecA gene makes penicillin-binding protein 2a, which reduces how well methicillin and related beta-lactam drugs can bind. MRSA has spread into separate clonal lineages that affect both humans and animals. These lineages fit the One Health idea, which links human, animal, and...

inhibitors of virion maturation and assembly

inhibitors-of-virion-maturation-and-assembly

HIV Protease Inhibitors and Maturation

HIV protease inhibitors block a key step in virus maturation. In human immunodeficiency virus (HIV), infected cells make two long precursor proteins called polyproteins. These are Gag and Gag-Pol. Gag provides the virus structure. Gag-Pol carries important viral enzymes, including reverse transcriptase, integrase, and protease. After these polyproteins are made, they move to the host cell membrane. There, they help build an immature viral particle that buds from the cell surface. Budding...

antiprotozoal agents

Leishmaniasis and Trypanothione Reductase

Leishmaniasis is a parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. Treatment often relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. The way these drugs work has not been fully clear. One important target is trypanothione reductase, or TR, an enzyme that helps keep Leishmania in redox balance. TR is not found in mammalian hosts, so it is a...

key terms and concepts

Learn how bacteria become antibiotic resistant, from beta-lactamases and efflux pumps to MRSA, VRE, VRSA, and drug-resistant Streptococcus pneumoniae.

How Bacteria Outsmart Antibiotics | JoVE K12

JoVE Core Microbiology provides an engaging introduction to the microbial world and its influence on health, industry, and the environment. This comprehensive collection covers key concepts such as microbial structure, metabolism, genetics, and ecology. It introduces essential laboratory techniques and microscopy methods through visually engaging animations. Corresponding scientist-in-action videos bridge classroom concepts with real-world research and applications.

microbiology

How Bacteria Outsmart Antibiotics

Description

Transcript

Tags